Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Atsushi Ohtsu, Takayuki Yoshino, Alfredo Falcone, Rocio Garcia-Carbonero, Guillem Argiles, Alberto F. Sobrero, Marc Peeters, Lukas Makris, Fabio M. Benedetti, Alberto Zaniboni, Yasuhiro Shimada, Kentaro Yamazaki, Yoshito Komatsu, Howard S. Hochster, Heinz-Josef Lenz, Ben Tran, Kenichiro Yoshida, Eric Van Cutsem, Robert J. Mayer, On Behalf of the RECOURSE Study Group
Institutions: National Cancer Center Hospital East, Azienda Ospedaliera Universitaria Pisana, Hospital Universitario 12 De Octubre, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Ospedale Policlinico San Martino, Antwerp University Hospital, Taiho Pharmaceutical (Japan), Fondazione Poliambulanza Istituto Ospedaliero, National Cancer Center Hospital, Shizuoka Cancer Center, Hokkaido University Hospital, Yale Cancer Center, USC Norris Comprehensive Cancer Center, The Royal Melbourne Hospital, Taiho Oncology (United States), Universitair Ziekenhuis Leuven, Dana-Farber Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2599189852